You can buy Olamart at the lowest price at Nextgen.ooo online pharmacy. Olaparib is a chemotherapeutic agent used to treat recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and a history of prior chemotherapy.
 
Olaparib is an inhibitor of poly-ADP-ribose polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit the growth of selected tumor cell lines in vitro and reduce tumor growth in mouse human cancer xenograft models both as monotherapy and after platinum-based chemotherapy. Enhanced cytotoxicity and antitumor activity following treatment with olaparib have been observed in cell lines and mouse tumor models deficient in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased PARP-DNA complex formation, leading to disruption of cellular homeostasis and cell death.
 
Olaparib is available as an oral tablet and was initially indicated as maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. On January 12, 2018, the FDA expanded the approved use of olaparib to include patients with chemotherapy-treated BRCA-mutated, HER2-negative metastatic breast cancer.
 
Moreover, in December 2018, the FDA additionally approved the categorization and use of olaparib as a first-line maintenance treatment for ovarian cancer, making the drug the first PARP inhibitor approved in the first-line maintenance setting. This new approval in primary care now allows patients who have undergone surgery and have had a complete or partial response to platinum-based therapy after a first cancer diagnosis to be treated with olaparib to reduce the risk of recurrence or significantly delay it. This approval is based on the results of the Phase 3 SOLO-1 study of olaparib, which demonstrated the agent’s ability to reduce the risk of disease progression or death by 70% in patients with BRCA-mutant advanced ovarian cancer who were in complete or partial response to platinum-based chemotherapy. The ability to offer this important first-line maintenance treatment option to eligible patients is expected to slow or even halt the natural history of disease progression.